CSL vs Telstra: Which ASX Blue Chip Offers Stronger Growth Potential?

CSL and Telstra are established ASX blue chips, but CSL offers stronger growth potential through new treatments, while Telstra appeals to investors seeking dividends and steady earnings.

CSL Ltd (ASX: CSL) has a market value of $93.68 billion and a dividend yield of 2.08%. With 100 years of experience, it develops plasma therapies, vaccines and medicines for serious and rare diseases, while investing in future growth.

On 8 October 2026, CSL announced an expansion of cooperation with Haemonetics Corporation, which aims to enhance the U.S. plasma collection network of the firm. CSL is expected to implement the newest generation plasmapheresis platform by Haemonetics in all the centers of the U.S. by the end of 2027. CSL has also agreed with Terumo BCT, the provider of its current Rika system, to support a smooth transition. This change is one of several steps aimed at improving collection network efficiency.

On 5 October 2026, CSL entered an exclusive agreement with Alentis Therapeutics to co-develop and co-promote lixudebart, a potential first in-class treatment for rare kidney and liver diseases. The drug is in a Phase 2 trial for AAV-RPGN, a serious autoimmune disease that can cause permanent kidney damage. It targets inflammation and fibrosis. Further development is planned for FSGS and PSC. CSL will pay US$355 million upfront with up to US$1.2 billion in commercial milestone payments. It will fund planned trials and related development, while global profits after commercialisation will be shared 55% to CSL and 45% to Alentis.

Telstra Group Ltd (ASX: TLS) has a market capitalisation of approximately A$54.9 billion. On 13 August 2026, TLS announced strong FY26 results and the progress on its Connected Future 30 strategy. Net profit after tax increased 2.7% to A$2.4 billion. The underlying EBITDAaL rose 4% to A$8.3 billion. Mobile customers grew by more than 270,000 and nearly 1,200 mobile sites were upgraded with 5G Advanced technology.

Telstra continued expanding its digital infrastructure, with more than 8,500 kilometres of fibre laid for its Aura Network and six routes ready for service. The company completed a A$1.25 billion share buy-back and announced another worth up to A$1 billion. Its annual dividend increased 10.5% to 21 cents per share, including a final dividend of 10.5 cents. These steps form part of its plans to improve network capacity and deliver shareholder returns.

Telstra has forecasted an underlying EBITDAaL of between A$8.5 billion and A$8.8 billion and a cash EBIT of A$4.75 billion and A$4.95 billion for FY27. Its focus will be on enhancing the reliability of its networks, expanding its fibre and satellite network, enhancing cybersecurity, and utilizing artificial intelligence. TLS is also focused on digital inclusion, affordable connectivity and helping employees adapt to new technology. By FY30, Telstra aims to achieve mid single digit annual growth in cash earnings and increase its underlying return on invested capital to 10%.

Which is the better buy?

CSL looks more attractive for long-term growth, with its global reach, expanding treatment pipeline and investment in innovation. Telstra remains a solid option for income-focused investors.

(Source: Company Report)